Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03746106
Other study ID # 13060
Secondary ID 5R01DK108722-02
Status Completed
Phase Phase 4
First received
Last updated
Start date January 28, 2019
Est. completion date August 10, 2023

Study information

Verified date August 2023
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Part 1, subjects will be administered thiamine, thiamine with metformin, and thiamine with trimethoprim. Part 2 will expand on Part 1 and subjects will be administered thiamine and thiamine with trimethoprim. The goal is to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine (Vitamin B1).


Description:

Thiamine is an essential vitamin meaning humans must consume thiamine from their diet in order to stay healthy. Low thiamine levels can lead to adverse events. Thiamine is absorbed in the intestine by a transporter protein. This is made by the SLC19A3 gene. The SLC19A3 gene provides instructions for making the thiamine transporter protein, which moves thiamine into cells. Certain drugs, like metformin and trimethoprim, have been shown to interrupt function of the SLC19A3 gene. Metformin is a first-line therapy for patients with Type 2 diabetes and is associated with improvements in diabetic complications. Trimethoprim is an anti-bacterial drug that is often prescribed to treat infections such as urinary tract infections. At different phases of this study, participants will be administered thiamine, thiamine with metformin, and/or thiamine with trimethoprim to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine. The levels of thiamine in the participants' blood and urine will be measured before and after taking thiamine or thiamine in combination with metformin and/or trimethoprim.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date August 10, 2023
Est. primary completion date August 10, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female between the ages of 18-65 years old. 2. Eats a wide variety of food and willing to consume study diet (i.e. not on a specific diet such as Atkins, Fodmap, etc.). 3. Written informed consent obtained from the subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: 1. Subjects who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. Self-reported severe food allergies or diet restrictions (vegans, vegetarians, Atkins, Fodmap, etc.) that would prevent consumption of study diets. 3. Subjects with extreme obesity (BMI > 35). 4. Subjects who are smokers or have smoked in the past year and/or have smoked or ingested THC/marijuana in the past week, or who are unwilling to comply with a 1-week washout. 5. Subjects with any disease affecting or impairing the function of the liver, kidney or heart. 6. Subjects with moderate to severe hypertension. 7. Subjects with diabetes mellitus, hyperthyroidism, hypothyroidism, cardiovascular disease, glaucoma. 8. Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal surgery. 9. Subjects with known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory diagnostics concerning these diseases will be performed within the present study. Volunteers who are cured of past HepC infection are eligible to participate with doctor's approval letter). 10. Alcohol use on average > 2 servings/day or > 14 servings/wk (Serving size: 12oz beer/4oz wine/2oz hard liquor) or self-reported binge drinking. 11. Subjects that are on vitamin B supplements or multi-vitamins or who have taken vitamin B supplements or multi-vitamins in the past 30 days, or are not willing to comply with a 30-day washout of vitamin B supplements. 12. Subjects with possible folate deficiency. 13. Subjects taking any other clinically significant drugs as judged by the investigator. 14. Subjects with a condition, disease, or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 15. Female subjects undergoing treatment for infertility or hormone replacement therapy (Volunteers using hormonal birth control will not be excluded). 16. Subjects who have taken antimalarials in the past 60 days. 17. Participating in another research study while participating in this research study. 18. Non-English speaking 19. Subjects with abnormal laboratory results at screening as judged by the investigator or study physician.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Trimethoprim
300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
Metformin
1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
Dietary Supplement:
Vitamin B1
5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.

Locations

Country Name City State
United States Jean Mayer USDA Human Nutrition Research Center on Aging Boston Massachusetts

Sponsors (4)

Lead Sponsor Collaborator
University of California, San Francisco National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Tufts University, University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Concentration-Time Curve (AUC 0-72h) Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles)
Primary Assess the effects of SLC19A3 inhibitors by Cmax In Parts 1 and 2, assess the effects of SLC19A3 inhibitors on the absorption and distribution of thiamine as measured by the change in maximum concentration (Cmax) between the combination arm(s) and single agent arm. As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles)
Secondary Investigate metabolic signatures reflecting the activity of TPP-dependent enzymes In Parts 1 and 2, investigate metabolic signatures reflecting the activity of TPP-dependent enzymes after the administration of thiamine or a combination of the thiamine and SLC19A3 inhibitor.
Metabolic signatures are measured in blood samples by LC-MS (measurement tool). The units of measure are relative abundance, which is expressed as a percentage of the total metabolites detected.
As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles)
Secondary Determine the effect of genetic variants of thiamine transporters The investigators will use Sanger Sequencing of two thiamine transporters (SLC19A2 and SLC19A3) to identify genetic variants in DNA extracted from blood samples. Sanger sequencing is done by Polymerase Chain Reaction (PCR) instrumentation and the unit of measure is single nucleotide polymorphism (SNPs) detected. As determined by blood/urine levels taken over the course of 2-3 cycles (each cycle is 3 days with a 5-14 day washout in between cycles)]
See also
  Status Clinical Trial Phase
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT03263442 - High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT05663164 - Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS) N/A
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Completed NCT04641104 - The Thiamine Administration After Cardiac Surgery Trial Phase 4
Recruiting NCT06298344 - The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease Early Phase 1
Completed NCT03626337 - Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR
Completed NCT05390086 - Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders
Recruiting NCT05480943 - Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
Active, not recruiting NCT04453761 - Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass Phase 4
Completed NCT03554668 - Systemic Inflammatory Response: Thiamine and Magnesium Status (Sir TaM Study)
Completed NCT01524315 - Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery Phase 4
Completed NCT03616288 - Trial of Thiamine Supplementation in Cambodia N/A
Completed NCT02464865 - Thiamin Deficiency in Obese Thai Children Phase 4
Completed NCT03228030 - Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial Phase 1